LHX:NYSEL3Harris Technologies, Inc. Analysis
Data as of 2026-03-10 - not real-time
$371.26
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
L3Harris (LHX) is trading at $371.26, just shy of its 52‑week high of $379.23, and sits comfortably above its 20‑day ($355.91), 50‑day ($342.17) and 200‑day ($291.29) SMAs, signaling a strong bullish trend. The RSI at 60.5 and a bullish MACD crossover (histogram +0.51) together with rising volume underscore continued upward momentum, while the stock currently respects a support zone near $329.28 and faces resistance around $379.23, offering a modest upside of roughly 4.5% per the DCF model. Recent material news – a $400 M THAAD interceptor contract and the appointment of Kenneth Sharp as CFO – adds concrete demand‑side catalysts that could sustain price appreciation in the near term.
Fundamentally, LHX posted $21.87 B in revenue with 2.3% YoY growth, solid operating (12.9%) and profit margins (7.3%), and generates robust free cash flow (~$2.73 B). The company pays a 1.35% dividend with a 56% payout ratio, suggesting dividend sustainability, but its forward PE of 27.3 and trailing PE of 43.5 are well above the industry average of 29.5, and a DCF fair value of $164.85 points to significant overvaluation despite strong cash generation and defensive sector tailwinds.
Fundamentally, LHX posted $21.87 B in revenue with 2.3% YoY growth, solid operating (12.9%) and profit margins (7.3%), and generates robust free cash flow (~$2.73 B). The company pays a 1.35% dividend with a 56% payout ratio, suggesting dividend sustainability, but its forward PE of 27.3 and trailing PE of 43.5 are well above the industry average of 29.5, and a DCF fair value of $164.85 points to significant overvaluation despite strong cash generation and defensive sector tailwinds.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish technical indicators (SMA alignment, RSI, MACD)
- Recent large defense contract (THAAD)
- Proximity to resistance limiting near‑term upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Steady earnings growth and strong free cash flow
- Attractive dividend yield with sustainable payout
- Projected upside of ~4.5% toward analyst target median of $390
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Long‑term defense spending tailwinds
- Consistent dividend income
- High valuation relative to fundamentals may cap long‑run returns
Key Metrics & Analysis
Financial Health
Revenue Growth2.30%
Profit Margin7.34%
P/E Ratio43.5
ROE8.19%
ROA4.23%
Debt/Equity60.61
P/B Ratio3.5
Op. Cash Flow$3.1B
Free Cash Flow$2.7B
Industry P/E29.5
Technical Analysis
TrendBullish
RSI60.5
Support$329.28
Resistance$379.23
MA 20$355.91
MA 50$342.17
MA 200$291.29
MACDBullish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$164.85
Target Price$388.11
Upside/Downside4.54%
GradeOvervalued
TypeGrowth
Dividend Yield1.35%
Risk Assessment
Beta0.47
Volatility33.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.